Valvular & structural heart disease
One-year outcomes after transcatheter aortic valve implantation with the latest-generation SAPIEN balloon-expandable valve: the S3U registry
Authors' conclusion
Compared with the S3, the S3U transcatheter heart valve was associated with similar 1-year clinical outcomes but reduced rates of mild PVL.
Study context
- Population
- Consecutive patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) at 12 European centres, October 2016–December 2020Propensity score (PS)-matched n = 992
- Participants
- 1,692 patients
- Exposure
- SAPIEN 3 Ultra vs SAPIEN 3 for transfemoral TAVI
- S3Un = 519
- S3n = 1,173reference
- Outcome
- All-cause death; composite of all-cause death, disabling stroke and hospitalisation for HF
- Follow-up
- 1 year
Methodological detailspropensity-score matched, multicentre, 12 European centres, consecutive patients
- Propensity-score matched
- Multicentre
- 12 European centres
- Consecutive patients
Main finding
As reported in the abstract
All-cause death
P = 0.743
Primary composite
P = 0.162
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Mild paravalvular leak | 0.63 (0.44–0.88) | P < 0.01 | |
| 0.512Odds ratio (log scale) |
Transprosthetic gradients
- No significant differences between the two groups
Original publication
One-year outcomes after transcatheter aortic valve implantation with the latest-generation SAPIEN balloon-expandable valve: the S3U registry. EuroIntervention. Published 24 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →